Filing Details

Accession Number:
0001209191-16-133849
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-25 17:07:47
Reporting Period:
2016-07-25
Filing Date:
2016-07-25
Accepted Time:
2016-07-25 17:07:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1628738 Audentes Therapeutics Inc. BOLD () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Ave., 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-07-25 627,867 $0.00 852,105 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2016-07-25 2,511,441 $0.00 3,363,546 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2016-07-25 1,071,992 $0.00 4,435,538 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2016-07-25 332,766 $0.00 4,768,304 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2016-07-25 33,334 $15.00 4,801,638 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series Seed Preferred Stock Disposition 2016-07-25 627,867 $0.00 627,867 $0.00
Common Stock Series A Preferred Stock Disposition 2016-07-25 2,511,441 $0.00 2,511,441 $0.00
Common Stock Series B Preferred Stock Disposition 2016-07-25 1,071,992 $0.00 1,071,992 $0.00
Common Stock Series C Preferred Stock Disposition 2016-07-25 332,766 $0.00 332,766 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of the issuer's Series Seed Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-208842) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
  2. These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP IV, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities.
  3. This report on Form 4 is jointly filed by GP IV, Advisors, and Isaly. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Jonathan Silverstein, a member of Advisors, to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
  4. Each share of the issuer's Series A Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
  5. Each share of the issuer's Series B Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
  6. Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.